Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 7/2012

01-07-2012 | Review Article

Antimuscarinic Treatment in Overactive Bladder

Special Considerations in Elderly Patients

Author: Dr Adrian S. Wagg

Published in: Drugs & Aging | Issue 7/2012

Login to get access

Abstract

Overactive bladder is a common condition that increases in prevalence in association with age. Antimuscarinic therapy remains the mainstay of pharmacological treatment for the condition, and there is an increasing body of evidence that supports the use of these drugs. Despite this, and because of concerns about associated adverse effects, older people are less likely to receive active treatment for their condition. This review considers some of the factors that need to be taken into account when using these medications.
Literature
1.
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29 (1): 4–20.PubMed
2.
Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc 2011; 59 (8): 1465–70.PubMedCrossRef
3.
4.
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50 (6): 1306–14; discussion 1314–5.PubMedCrossRef
5.
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20 (6): 327–36.PubMed
6.
Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (11 Suppl.): S574–9.PubMed
7.
Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997; 26 (5): 367–74.PubMedCrossRef
8.
Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148 (5): 565–78.PubMedCentralPubMedCrossRef
9.
Perry S, Shaw C, Assassa P, et al. An epidemiological study to establish the prevalence of urinary symptoms and felt need in the community: the Leicestershire MRC Incontinence Study. Leicestershire MRC Incontinence Study Team. J Public Health Med 2000; 22 (3): 427–34.PubMedCrossRef
10.
Choo MS, Song C, Kim JH, et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol 2005; 174 (1): 201–4.PubMedCrossRef
11.
Kraus SR, Ruiz-Cerda JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76 (6): 1350–7.PubMedCrossRef
12.
Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4 (1): 14–24.PubMedCrossRef
13.
Michel MC, Barendrecht MM. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther 2008; 117 (3): 297–312.PubMedCrossRef
14.
Wagg A, Fahey A, Siddiqui E. Persistence with oral antimuscarinics used for the treatment of overactive bladder in different age groups of patients in general practice. Age Ageing 2010; 39 Suppl. 1: i39–40.CrossRef
15.
Bartus RT. On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495–529.PubMedCrossRef
16.
Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6 (1): 51–8.PubMedCrossRef
17.
Perry E, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol 2003; 54: 235–8.PubMedCrossRef
18.
Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry 2009; 24: 578–84.PubMedCrossRef
19.
Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003; 60 (2): 198–203.PubMedCrossRef
20.
Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009; 169 (14): 1317–24.PubMedCentralPubMedCrossRef
21.
Fox C, Richardson K, Maidmant ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011; 59 (8): 1477–83.PubMedCrossRef
22.
Schubert CC, Boustani M, Callahan CM, et al. Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc 2006; 54 (1): 104–9.PubMedCrossRef
23.
Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46 (1): 8–13.PubMed
24.
Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163 (22): 2716–24.PubMedCrossRef
25.
Mittal V, Muralee S, Williamson D, et al. Review: delirium in the elderly: a comprehensive review. Am J Alzheimers Dis Other Demen 2011; 26 (2): 97–109.PubMedCrossRef
26.
Uusvaara J, Pitkala KH, Kautiainen H, et al. Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: a prospective study. Drugs Aging 2011; 28 (2): 131–8.PubMedCrossRef
27.
Luukkanen MJ, Uusvaara J, Laurila JV, et al. Anticholinergic drugs and their effects on delirium and mortality in the elderly. Dement Geriatr Cogn Dis Extra 2011; 1 (1): 43–50.PubMedCentralPubMedCrossRef
28.
Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349 (23): 2274–5.PubMedCrossRef
29.
30.
Salvatore S, Serati M, Cardozo L, et al. Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol 2007; 197 (2): e8.PubMedCrossRef
31.
Movig KL, Egberts AC, Lenderink AW, et al. Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice. J Am Geriatr Soc 2001; 49 (2): 234–5.PubMedCrossRef
32.
Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173 (2): 493–8.PubMedCrossRef
33.
Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50 (2): 317–26.PubMedCrossRef
34.
Kay GG, Abou-Donia MB, Messer Jr WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53 (12): 2195–201.PubMedCrossRef
35.
Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008 Nov; 62 (11): 1792–800.PubMedCentralPubMedCrossRef
36.
Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009; 8 (6): 615–26.PubMedCrossRef
37.
Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64 (9): 1294–300.PubMedCrossRef
38.
Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41 (6): 636–44.PubMedCrossRef
39.
Herberg K. Alltags-und Verkehrrssicherheit unter Inkontinenz-Medikation. Neue Untersuchungen zum Sicherheitspotential urologischer Anticholinergika. Med Welt 1999; 50: 217–22.
40.
Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects [abstract]. Proceedings of the 36th meeting of the International Continence Society; 2006 Nov 27–Dec 1; Christchurch.
41.
Rait G, Fletcher A, Smeeth L, et al. Prevalence of cognitive impairment: results from the MRC trial of assessment and management of older people in the community. Age Ageing 2005; 34 (3): 242–8.PubMedCrossRef
42.
Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987; 44 (5): 418–26.PubMedCrossRef
43.
Koller WC. Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 1984; 20 (2): 307–11.PubMedCrossRef
44.
Perlmuter LC, Hakami MK, Hodgson-Harrington C, et al. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am J Med 1984; 77 (6): 1043–8.PubMedCrossRef
45.
Gaudino EA, Chiaravalloti ND, DeLuca J, et al. A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14(1): 32–44.PubMed
46.
Duka T, Townshend JM, Collier K, et al. Impairment in cognitive functions after multiple detoxifications in alcoholic inpatients. Alcohol Clin Exp Res 2003; 27 (10): 1563–72.PubMedCrossRef
47.
Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 2004; 52 (12): 2082–7.PubMedCrossRef
48.
Blazer 2nd DG, Federspiel CF, Ray WA, et al. The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontol 1983; 38 (1): 31–5.PubMedCrossRef
49.
Gill S, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165 (7): 808–13.PubMedCrossRef
50.
Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf 2011; 10(5): 751–65.PubMedCrossRef
51.
52.
Jouven X, Empana J-P, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 1951–8.PubMedCrossRef
53.
Orso F, Baldasseroni S, Maggioni AP. Heart rate in coronary syndromes and heart failure. Prog Cardiovasc Dis 2009; 52 (1): 38–45.PubMedCrossRef
54.
Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 2007; 100 (5): 1007–14.PubMed
55.
Andersson KE, Sarawate C, Kahler KH, et al. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2009 Nov 17.
56.
Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20 (6): 392–9.PubMed
57.
Schiffers M, Sauermann P, Schurch B, et al. The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 2010 Oct; 28 (5): 651–6.PubMedCrossRef
58.
Michel MC, Wetterauer U, Vogel M, et al. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 2008; 31 (6): 505–14.PubMedCrossRef
59.
Hussain RM, Hartigan-Go K, Thomas SH, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996; 41 (1): 73–5.PubMedCrossRef
60.
Abrams P, Cardozo L, Chapple C, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006; 13 (6): 692–8.PubMedCrossRef
61.
Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or =50 years. J Cardiovasc Pharmacol Ther 2008; 13 (4): 241–51.PubMedCrossRef
62.
Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin pharmacol 1994; 47 (4): 337–43.PubMedCrossRef
63.
Alzayer R, Hughes J, Parsons R, et al. Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents. Qual Prim Care 2010; 18(3): 189–99.PubMed
64.
Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 2011; 72 (2): 186–96.PubMedCentralPubMedCrossRef
65.
Hopcraft MS, Tan C. Xerostomia: an update for clinicians. Aust Dent J 2010; 55 (3): 238–44; quiz 353.PubMedCrossRef
66.
Pajukoski H, Meurman JH, Halonen P, et al. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92 (6): 641–9.PubMedCrossRef
67.
68.
Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011;6(2):e16718.PubMedCentralPubMedCrossRef
69.
Herschorn S, Pommerville P, Stothers L, et al. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin 2011; 27 (2): 375–82.PubMedCrossRef
70.
71.
Coyne KS, Cash B, Kopp Z, et al. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int 2011; 107 (2): 254–61.PubMedCrossRef
72.
Donald IP, Smith RG, Cruikshank JG, et al. A study of constipation in the elderly living at home. Gerontology 1985; 31 (2): 112–8.PubMedCrossRef
73.
Kinnumen O. Study of constipation in a geriatric hospital, day hospital, old people’s home and at home. Aging (Milano) 1991; 3 (2): 161–70.
74.
Harari D, Gurwitz JH, Avorn J, et al. How do older persons define constipation? Implications for therapeutic management. J Gen Int Med 1997; 12 (1): 63–6.CrossRef
75.
Meek PD, Evang SD, Tadrous M, et al. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011; 56 (1): 7–18.PubMedCrossRef
76.
Arnett 3rd RH, Blank LA, Brown AP, et al. National health expenditures, 1988. Office of National Cost Estimates. Health Care Financ Rev 1990; 11 (4): 1–41.
77.
Gupta S, Rappaport HM, Bennett LT. Inappropriate drug prescribing and related outcomes for elderly Medicaid beneficiaries residing in nursing homes. Clin Ther 1996; 18 (1): 183–96.PubMedCrossRef
78.
Golden AG, Preston RA, Barnett SD, et al. Inappropriate medication prescribing in homebound older adults. J Am Geriatr Soc 1999; 47 (8): 948–53.PubMed
79.
O’Connor K, O’Mahony D. Drugs and ageing. In: Liston R, Mulkerrin EC, editors. Medicine for older patients: cases and practice. Dublin: Eireann Healthcare Publications, 2003.
80.
Royal College of Physicians. Medication for older people. London: Royal College of Physicians, 1997.
81.
Kennerfalk A, Ruigomez A, Wallander MA, et al. Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 2002; 36 (5): 797–803.PubMedCrossRef
82.
Witte LP, Mulder WM, de la Rosette JJ, et al. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 2009; 19 (1): 13–9.PubMedCrossRef
83.
Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999; 33 (11): 1173–6.PubMedCrossRef
84.
Fillit HM, Rockwood K, Woodhouse K. Brocklehurst’s textbook of geriatric medicine and gerontology. 7th ed. Philadelphia (PA): Saunders/Elsevier 2010.
85.
Shimp LA, Wells TJ, Brink CA, et al. Relationship between drug use and urinary incontinence in elderly women. Drug Intell Clin Pharm 1988; 22 (10): 786–7.PubMed
86.
Alling Moller L, Lose G, Jorgensen T. Risk factors for lower urinary tract symptoms in women 40 to 60 years of age. Obstet Gynecol 2000; 96 (3): 446–51.PubMedCrossRef
87.
Van Oyen H, Van Oyen P. Urinary incontinence in Belgium: prevalence, correlates and psychosocial consequences. Acta Clin Belg 2002; 57 (4): 207–18.PubMedCrossRef
88.
Ruby CM, Hanlon JT, Boudreau RM, et al. The effect of medication use on urinary incontinence in community-dwelling elderly women. J Am Geriatr Soc 2010; 58 (9): 1715–20.PubMedCentralPubMedCrossRef
89.
Landi F, Cesari M, Russo A, et al. Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community. Clin Pharmacol Ther 2002; 72 (6): 729–34.PubMedCrossRef
90.
Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002; 11 (4): 271–9.PubMedCrossRef
91.
Hashimoto M, Imamura T, Tanimukai S, et al. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet 2000; 356 (9229): 568.PubMedCrossRef
92.
Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97 (1): 116–20.PubMedCrossRef
93.
Starr J. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer’s disease. J Am Geriatr Soc 2007; 55: 800–1.PubMedCrossRef
94.
Siegler EL, Reidenberg M. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004; 75 (5): 484–8.PubMedCrossRef
95.
Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165 (7): 808–13.PubMedCrossRef
96.
Sink K, Thomas 3rd J, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008; 56: 847–53.PubMedCrossRef
97.
Isik AT, Celik T, Bozoglu E, et al. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009; 13 (8): 672–6.PubMedCrossRef
98.
Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc 2009; 57 (8): 1515–7.PubMedCrossRef
Metadata
Title
Antimuscarinic Treatment in Overactive Bladder
Special Considerations in Elderly Patients
Author
Dr Adrian S. Wagg
Publication date
01-07-2012
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 7/2012
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/BF03262272

Other articles of this Issue 7/2012

Drugs & Aging 7/2012 Go to the issue

Original Research Article

Hospitalization as a Turning Point for Sleep Medication Use in Older Adults

Therapy In Practice

Management of Seizures following a Stroke

Current Opinion

Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients

Original Research Article

Pharmacist-Led Medication Review to Identify Medication-Related Problems in Older People Referred to an Aged Care Assessment Team

Review Article

Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions

Original Research Article

Content Validity and Inter-Rater Reliability of an Instrument to Characterize Unintentional Medication Discrepancies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits